Mirum Pharmaceuticals (MIRM) Revenue & Revenue Breakdown
Mirum Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$521.31M
Latest Revenue (Q)
$133.01M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Mirum Pharmaceuticals Revenue by Period
Mirum Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $521.31M | 54.74% |
| 2024-12-31 | $336.89M | 80.76% |
| 2023-12-31 | $186.37M | 141.85% |
| 2022-12-31 | $77.06M | 302.66% |
| 2021-12-31 | $19.14M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Mirum Pharmaceuticals generated $521.31M in revenue during NA 2025, up 54.74% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Mirum Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $133.01M | 4.09% |
| 2025-06-30 | $127.78M | 14.52% |
| 2025-03-31 | $111.58M | 12.24% |
| 2024-12-31 | $99.41M | 10.00% |
| 2024-09-30 | $90.38M | 16.05% |
| 2024-06-30 | $77.88M | 12.50% |
| 2024-03-31 | $69.22M | -0.48% |
| 2023-12-31 | $69.55M | 45.74% |
| 2023-09-30 | $47.73M | 27.28% |
| 2023-06-30 | $37.50M | 18.67% |
| 2023-03-31 | $31.60M | 13.23% |
| 2022-12-31 | $27.91M | 48.59% |
| 2022-09-30 | $18.78M | 7.41% |
| 2022-06-30 | $17.48M | 35.62% |
| 2022-03-31 | $12.89M | 310.83% |
| 2021-12-31 | $3.14M | -37.24% |
| 2021-09-30 | $5.00M | -54.55% |
| 2021-06-30 | $11.00M | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | - |
Mirum Pharmaceuticals generated $133.01M in revenue during Q3 2025, up 4.09% compared to the previous quarter, and up 170.80% compared to the same period a year ago.
Mirum Pharmaceuticals Revenue Breakdown
Mirum Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Product | $521.31M | $336.41M | $178.87M | $75.06M | $3.14M |
| License and Other Revenue | - | $479.00K | - | - | - |
| License Revenue | - | - | $7.50M | - | - |
| License | - | - | - | $2.00M | $16.00M |
Mirum Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $148.93M | $133.01M | $127.78M | $111.58M | $177.19M | $90.30M | $68.92M | $69.55M | $47.73M | $32.50M | $29.10M | $27.91M | $18.78M | $17.48M | $10.89M |
| License and Other Revenue | - | - | - | - | $99.00K | $75.00K | $305.00K | - | - | - | - | - | - | - | - |
| License Revenue | - | - | - | - | - | - | - | - | $7.50M | - | - | - | - | - | - |
| License | - | - | - | - | - | - | - | - | - | $5.00M | $2.50M | - | - | - | $2.00M |
Mirum Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Product (100.00%).
Mirum Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 | Dec 23 |
|---|---|---|---|
| UNITED STATES | $401.55M | $274.17M | $146.70M |
| Non-US | $119.77M | - | - |
| Rest of the World | - | $62.24M | - |
| Rest of World | - | - | $32.17M |
Mirum Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (77.03%), and Non-US (22.97%).
Quarterly Revenue by Country
| Country | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | $115.38M | $103.71M | $95.53M | $86.92M | $144.16M | $73.91M | $56.11M |
| Rest Of World | - | $29.30M | $32.25M | $24.66M | $16.40M | $12.81M | - |
Mirum Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Dec 25: UNITED STATES (100.00%).
Mirum Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals | $957.80M | $278.63M |
| TLX | Telix Pharmaceuticals | $783.21M | $7.41M |
| RARE | Ultragenyx Pharmaceutical | $673.00M | $159.93M |
| MIRM | Mirum Pharmaceuticals | $521.31M | $133.01M |
| ADMA | ADMA Biologics | $510.17M | $134.22M |
| TVTX | Travere Therapeutics | $490.73M | $164.86M |
| LGND | Ligand Pharmaceuticals | $268.09M | $115.46M |
| SLNO | Soleno Therapeutics | $190.41M | $66.02M |
| DYN | Dyne Therapeutics | - | - |
| PRAX | Praxis Precision Medicines | - | - |
| BLTE | Belite Bio | - | - |